473-85-8

Basic information

• Product Name: (R,R)-3,4-Dihydroxytetrahydrofuran
• Synonyms: (R,R)-3,4-Dihydroxytetrahydrofuran
• CAS NO: 473-85-8
• Molecular Formula: C₄H₈O₃
• Molecular Weight: 104.10452
• Mol File: 473-85-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R,R)-3,4-Dihydroxytetrahydrofuran(CAS DataBase Reference)
• NIST Chemistry Reference: (R,R)-3,4-Dihydroxytetrahydrofuran(473-85-8)
• EPA Substance Registry System: (R,R)-3,4-Dihydroxytetrahydrofuran(473-85-8)

Safety Data

• Hazardous Substances Data: 473-85-8(Hazardous Substances Data)

Usage

General Description

(R,R)-3,4-Dihydroxytetrahydrofuran is a chemical compound with the molecular formula C4H8O3. It is a tetrahydrofuran derivative that contains two hydroxyl groups on the 3 and 4 positions of the ring. (R,R)-3,4-Dihydroxytetrahydrofuran is chiral, meaning it has two stereoisomers, (R,R) and (S,S). (R,R)-3,4-Dihydroxytetrahydrofuran has been studied for its potential use in organic synthesis and as a building block for the synthesis of natural products and pharmaceuticals. It has also been investigated for its antioxidant properties and potential applications in the food and cosmetic industries.

Upstream product

• 285-69-8 3,4-epoxytetrahydrofuran 

Downstream Products

• 109-99-9 tetrahydrofuran 
• 71-36-3 butan-1-ol 

Relevant articles and documents

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Quinazoline compound and anti-tumor agent containing said compound as an active ingredient

A quinazoline compound of the formula (I): STR1 wherein Z means a group of the formula: STR2 (X is CH2, CHOH, CHOCH3, or O, and n is 1 to 3), or a group of the formula: STR3 (A is H or CH3, and B is --CH2 OH, or